NCT06313463View on ClinicalTrials.gov

Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy

PHASE3RecruitingINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

September 30, 2031

Study Completion Date

December 31, 2035

Conditions
Breast Neoplasms
Interventions
DRUG

Carrellizumab + Capecitabine

Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Carrellizumab 200mg IV D1（Q3W），8 cycles in total

DRUG

Placebo + Capecitabine

Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Placebo 200mg IV D1（Q3W），8 cycles in total

Trial Locations (1)

510120

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER